{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-029124","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2023-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.019652+00:00","generated_at":"2026-06-14T03:59:53.001760+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AVROBIO approves $250K in transaction bonuses for CEO and CTO tied to cystinosis program sale","bullets":["Transaction bonuses of $150k for President/Interim CEO/CFO Erik Ostrowski and $100k for CTO Azadeh Golipour, payable in three installments after Asset Sale closing.","Bonuses contingent on closing of previously announced sale of cystinosis gene therapy program; forfeiture if resignation/termination before payment.","Stockholders elected directors Ian Clark and Annalisa Jenkins as Class II directors for term until 2026 annual meeting.","Ratification of Ernst & Young as independent auditor for FY2023 with over 34 million votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-029124","json":"https://secwatch.observer/filing/0001140361-23-029124.json","markdown":"https://secwatch.observer/filing/0001140361-23-029124.md","text":"https://secwatch.observer/filing/0001140361-23-029124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123029124/0001140361-23-029124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123029124/brhc20054224_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:59:53.001760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"178083bf78243e5d872f4c6196c0cc126b85f517","claim":"Tectonic Therapeutic, Inc. shareholders approved Election of two Class II directors at the 2023-06-06 meeting.","evidence_excerpt":"The Company’s stockholders elected the two director nominees listed below to serve as Class II directors until the Company’s 2026 annual meeting of stockholders, with the votes cast as follows: Director Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 20,810,217 5,332,015 8,660,564 Annalisa Jenkins, M.B.B.S., F.R.C.P. 16,685,601 9,456,631 8,660,564","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123029124/0001140361-23-029124-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"},{"claim_id":"9c3d00a19ce1a9595d0071a2b75080c609e47fec","claim":"Tectonic Therapeutic, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-06 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with the votes cast as follows: Votes For Votes Against Abstentions Broker Non-Votes 34,092,579 33,201 677,016 --","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123029124/0001140361-23-029124-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}